Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors
Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) announced that the National Medical Products Administration (NMPA)...
Clinical trial approval / initiation
Huadong Medicine DR10624 Gets NMPA Nod for Hypertriglyceridemia Study
Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary Doer Biologics has received National...
Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial
Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has...
CMS-D017 Gets NMPA Approval for Complement-Mediated Kidney Disease Study
China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA) has...
United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial
United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products Administration (NMPA) has...
Wuhan YZY Biopharma Gets FDA Nod for M701 Phase Ib/II MPE Study
Wuhan YZY Biopharma Co., Ltd (HKG: 2496) announced that the U.S. Food and Drug Administration...
BeBetter Med BEBT-701 Approved for Hypertension siRNA Trial
Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced that the National Medical Products Administration...
CMS-D017 Gets NMPA Nod for PNH Clinical Trial
China Medical System Holdings (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has...
CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials
CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the National Medical Products Administration (NMPA) has approved...
United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial
United Laboratories International Holdings Ltd (HKG: 3933) announced that the U.S. Food and Drug Administration (FDA)...
MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study
MicuRx Pharmaceuticals Inc., (SHA: 688373) a Sino‑US biopharmaceutical company, announced it has received approval from...
Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo
Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced that the National Medical Products Administration (NMPA)...
Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced it has received National Medical Products Administration (NMPA)...
Betta Pharmaceuticals’ BPI-572270 RAS Inhibitor Gets NMPA Nod for Solid Tumor Trials
Betta Pharmaceuticals (SHE: 300558) announced that the National Medical Products Administration (NMPA) has approved the...
Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30
Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in a 13‑week...
Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that China’s National Medical Products Administration (NMPA)...
Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that China’s National Medical Products...
Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that SHR‑7877 has received National Medical Products...
Henlius’s HLX701 Gets NMPA Nod for Phase Ib/II Advanced CRC Combination Study
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has...
Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell...